Cifurtilimab

N/A

Report date: 2025/01/08 11:53:11

Base Information

Drug NameCifurtilimab
Drug Alias NameSEA-CD40SEA-1C10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeagen Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsNeoplasm MetastasisHead and Neck NeoplasmsPancreatic Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A